Clinical Trials in Washington

Showing 2041-2060 of 4,564 trials

CGMIS 48-hour Feasibility Study

NCT05562206

This is a single center, single arm non-randomized study of 48-hour CGMIS wear duration incorporating two meal-challenge tests to explore the performance of a single insertion combined glucose-sensing insulin delivery cannula.

Type1diabetes

Pacific Diabetes Technologies20 participantsStarted Aug 2022

Renton, Washington, United States

TERMINATEDPhase 336 miles

Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee

NCT03349645

This Open Label Extension (OLE) study will assess the safety of long-term treatment with a 4 mL intra-articular injection of Ampion™ in adults with pain due to severe osteoarthritis of the knee

Severe Osteoarthritis of the Knee

Ampio Pharmaceuticals. Inc.94 participantsStarted Dec 2017

Birmingham, Alabama, United States • Encinitas, California, United States • Fullerton, California, United States +8 more locations

COMPLETEDPhase 242 miles

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

NCT01767194

This randomized phase II trial studies how well irinotecan hydrochloride and temozolomide with temsirolimus or dinutuximab work in treating younger patients with neuroblastoma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as irinotecan hydrochloride and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as dinutuximab, may find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether giving irinotecan hydrochloride and temozolomide together with temsirolimus or dinutuximab is more effective in treating neuroblastoma.

GanglioneuroblastomaRecurrent Neuroblastoma

National Cancer Institute (NCI)73 participantsStarted Feb 2013

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • Little Rock, Arkansas, United States +154 more locations

CGMIS 48-hour Feasibility Study

Open Label Extension to Assess the Safety of Long-Term Treatment With Ampion for Severe Osteoarthritis (OA) of the Knee

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

Find Trials by Condition in Washington

Assisted Partner Services and HIVST in Western Kenya

A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention

Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke

Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors

(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

National Registry for Ichthyosis and Related Disorders

Chronic Total Occlusion Percutaneous Coronary Intervention Study

Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)

Precision Event Monitoring for Patients With Heart Failure Using HeartLogic

Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1

The Impact of "First-Line" Rhythm Therapy on AF Progression

A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma

Real-World Experience Study of Elagolix For the Treatment of Endometriosis in Canada

Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement

Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC